Flerie
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.
NET ASSET VALUE – 30 September 2026
MARKN.
On the 30 September 2026 Flerie AB's Net Asset Value (NAV) was SEK 3,113 million and NAV per share was SEK 35.91. Return on NAV per share in the month was -6.8%.
| Allocation of NAV | Share of portfolio company | Fair value (MSEK) | Part of NAV per share (SEK) | Share of NAV |
| Product Development | ||||
| Lipum | 100% | 348 | 4.01 | 11.2% |
| Prokarium | 50% | 296 | 3.41 | 9.5% |
| Atrogi | 47% | 215 | 2.48 | 6.9% |
| KAHR Medical | 34% | 214 | 2.47 | 6.9% |
| Microbiotica | 10% | 191 | 2.20 | 6.1% |
| Bonsai Biotherapeutics | 100% | 158 | 1.82 | 5.1% |
| AnaCardio | 9% | 105 | 1.22 | 3.4% |
| Mendus | 22% | 89 | 1.03 | 2.9% |
| Xintela | 60% | 88 | 1.02 | 2.8% |
| Xspray Pharma | 17% | 85 | 0.98 | 2.7% |
| Geneos Therapeutics | 12% | 71 | 0.82 | 2.3% |
| EpiEndo Pharmaceuticals | 9% | 56 | 0.65 | 1.8% |
| Vitara Biomedical | 9% | 51 | 0.58 | 1.6% |
| Egetis Therapeutics | 1% | 43 | 0.50 | 1.4% |
| Buzzard Pharmaceuticals | 15% | 33 | 0.38 | 1.1% |
| Amarna Therapeutics | 58% | 11 | 0.13 | 0.4% |
| Strike Pharma | 18% | 11 | 0.12 | 0.3% |
| Empros Pharma | 79% | 0 | 0.00 | 0.0% |
| Total | 2,065 | 23.82 | 66.3% | |
| Commercial Growth | ||||
| Symcel | 30% | 211 | 2.43 | 6.8% |
| NorthX Biologics | 61% | 202 | 2.33 | 6.5% |
| Chromafora | 29% | 149 | 1.72 | 4.8% |
| Nanologica | 50% | 50 | 0.58 | 1.6% |
| Frontier Biosolutions | 2% | 27 | 0.31 | 0.9% |
| Bohus Biotech | 45% | 22 | 0.26 | 0.7% |
| Total | 661 | 7.63 | 21.2% | |
| Assets and liabilities related to Portfolio companies | 131 | 1.51 | 4.2% | |
| Other assets and liabilities | 256 | 2.95 | 8.2% | |
| Net Asset Value | 3,113 | 35.91 | 100.0% | |
| Datum | 2026-10-07, kl 08:00 |
| Källa | MFN |